Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer ; volume:8 ; number:1 ; day:31 ; month:1 ; year:2013 ; pages:1-10 ; date:12.2013
Radiation oncology ; 8, Heft 1 (31.1.2013), 1-10, 12.2013
- Urheber
-
Ju, Andrew W.
- Beteiligte Personen und Organisationen
-
Wang, Hongkun
Oermann, Eric K.
Sherer, Benjamin A.
Uhm, Sunghae
Chen, Viola J.
Pendharkar, Arjun V.
Hanscom, Heather N.
Kim, Joy S.
Lei, Siyuan
Suy, Simeng
Lynch, John H.
Dritschilo, Anatoly
Collins, Sean P.
SpringerLink (Online service)
- DOI
-
10.1186/1748-717X-8-30
- URN
-
urn:nbn:de:1111-201604095684
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ju, Andrew W.
- Wang, Hongkun
- Oermann, Eric K.
- Sherer, Benjamin A.
- Uhm, Sunghae
- Chen, Viola J.
- Pendharkar, Arjun V.
- Hanscom, Heather N.
- Kim, Joy S.
- Lei, Siyuan
- Suy, Simeng
- Lynch, John H.
- Dritschilo, Anatoly
- Collins, Sean P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
Hypofractionated radiotherapy for prostate cancer
SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment
Hypofractionated radiotherapy for localized prostate cancer
Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
Normal tissue toxicity after small field hypofractionated stereotactic body radiation
Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma
Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
Hypofractionated radiotherapy for prostate cancer
SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment
Hypofractionated radiotherapy for localized prostate cancer
Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
Normal tissue toxicity after small field hypofractionated stereotactic body radiation
Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma
Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
Hypofractionated radiotherapy for prostate cancer
SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment
Hypofractionated radiotherapy for localized prostate cancer
Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
Normal tissue toxicity after small field hypofractionated stereotactic body radiation
Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience